European Commission Grants NLX-112 Orphan Medicinal Product Designation for Spinocerebellar Ataxia
Following a recent positive recommendation from the Committee for Orphan Medicinal Products, the European Commission has granted NLX-112 (Neurolixis), a highly selective serotonin 5-HT1A receptor agonist, orphan medicinal product designation for the …